日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Projected life-year gains with semaglutide in individuals with cardiovascular disease without type 2 diabetes in the UK

英国接受司美格鲁肽治疗的非2型糖尿病心血管疾病患者的预期寿命延长

Van Sloten, Thomas; Hageman, Steven H J; Westerink, Jan; Capucci, Silvia; Diogo da Rocha Fernandes, João; Holloway, Sara; Pijper, Andrew; Tikhonovsky, Natalie; Emerson, Scott; Lincoff, A Michael; Plutzky, Jorge; Lingvay, Ildiko

2023 European Society of Cardiology guidelines for the management of cardiovascular disease in patients with diabetes : Statement of endorsement by the NVVC

2023年欧洲心脏病学会糖尿病患者心血管疾病管理指南:NVVC认可声明

Martens, Fabrice M A C; Visseren, Frank L J; Westerink, Jan; Spee, Ruud F; Saloua, El Messaoudi; Mosterd, Arend; Handoko, Louis M; Leening, Maarten J G; Römer, Tjeerd J; Slootweg, Andries; van Bon, Arianne C; Hemels, Martin E W

Cardiovascular risk and lifetime benefit from preventive treatment in type 2 diabetes: A post hoc analysis of the CAPTURE study

型糖尿病患者心血管风险及预防性治疗的终生获益:CAPTURE 研究的事后分析

Østergaard, Helena Bleken; Humphreys, Valerie; Hengeveld, Ellen Margo; Honoré, Julie Broe; Mach, François; Visseren, Frank L J; Westerink, Jan; Yadav, Gourav; Mosenzon, Ofri

Low-grade inflammation as a risk factor for cardiovascular events and all-cause mortality in patients with type 2 diabetes

低度炎症是2型糖尿病患者发生心血管事件和全因死亡的危险因素

Sharif, Shahnam; Van der Graaf, Y; Cramer, M J; Kapelle, L J; de Borst, G J; Visseren, Frank L J; Westerink, Jan

Development of a clinical decision tool to reduce diagnostic testing for primary aldosteronism in patients with difficult-to-control hypertension

开发一种临床决策工具,以减少难治性高血压患者原发性醛固酮增多症的诊断性检查。

van Kleef, Monique E A M; Visseren, Frank L J; Westerink, Jan; Bots, Michiel L; Blankestijn, Peter J; van der Graaf, Yolanda; Spiering, Wilko

Intimal and medial calcification in relation to cardiovascular risk factors

内膜和中膜钙化与心血管危险因素的关系

Zwakenberg, Sabine R; de Jong, Pim A; Hendriks, Eva J; Westerink, Jan; Spiering, Wilko; de Borst, Gert J; Cramer, Maarten J; Bartstra, Jonas W; Doesburg, Teddo; Rutters, Femke; van der Heijden, Amber A; Schalkwijk, Casper; Schurgers, Leon J; van der Schouw, Yvonne T; Beulens, Joline W J

Mediation analysis of the relationship between type 2 diabetes and cardiovascular events and all-cause mortality: Findings from the SMART cohort

SMART队列研究揭示2型糖尿病与心血管事件和全因死亡率之间关系的中介效应分析

Sharif, Shahnam; Groenwold, Rolf H H; van der Graaf, Yolanda; Berkelmans, Gijs F N; Cramer, Maarten J; Visseren, Frank L J; Westerink, Jan

Thyroid-stimulating hormone levels in the normal range and incident type 2 diabetes mellitus

促甲状腺激素水平在正常范围内与2型糖尿病发病率

de Vries, T I; Kappelle, L J; van der Graaf, Y; de Valk, H W; de Borst, G J; Nathoe, H M; Visseren, F L J; Westerink, Jan

Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials

吡格列酮与心血管疾病的二级预防:一项随机对照试验的荟萃分析

de Jong, Marit; van der Worp, H Bart; van der Graaf, Yolanda; Visseren, Frank L J; Westerink, Jan

The influence of baseline risk on the relation between HbA1c and risk for new cardiovascular events and mortality in patients with type 2 diabetes and symptomatic cardiovascular disease

基线风险对2型糖尿病合并症状性心血管疾病患者HbA1c与新发心血管事件和死亡风险之间关系的影响

Bots, Sophie H; van der Graaf, Yolanda; Nathoe, Hendrik M W; de Borst, Gert Jan; Kappelle, Jaap L; Visseren, Frank L J; Westerink, Jan